Table 1.
Demographic, Clinical and Laboratory Features of RA Subjects and HCs
RA n=84 | HCs n=79 | |
---|---|---|
Age, years | 59.0 ± 9.9 | 46.7 ± 11.6 |
Female sex, n (%) | 65 (77.38) | 54 (68.35) |
Disease duration, months | 145 ± 134 | – |
ACPA positivity, n (%) | 68.6 | – |
RF positivity, n (%) | 74.5 | – |
HAQ (0–3) | 0.92 ± 0.73 | – |
DAS-28 | 3.72 ± 1.38 | – |
CRP, mg/dL | 0.88 ± 0.96 | – |
ESR, mm/h | 30.7 ± 25.8 | – |
Steroids use, n (%) | 43.4 | – |
DMARDs use, n (%) | 66.3 | – |
Anti-TNF use, n (%) | 24.1 | – |
Tocilizumab use, n (%) | 12 | – |
Abatacept use, n (%) | 4.9 | – |